Genenta Science

Historical price data

Genenta Science's mission is to develop durable, patient-specific gene therapies for solid tumors by engineering hematopoietic stem cells to produce therapeutics directly within the tumor microenvironment. Its lead candidate, Temferon, has progressed through Phase 1/2 clinical trials for glioblastoma multiforme (GBM). In a significant strategic pivot, the company is evolving into Saentra Forge, aiming to build a multi-pillar industrial group through acquisitions in biotechnology and national-security regulated sectors, while continuing to advance its core Temferon platform.

The Temferon platform involves genetically engineering a patient's own hematopoietic stem cells (HSPCs) to produce immunomodulatory agents, such as interferon-alpha, specifically within the tumor microenvironment via differentiated myeloid cells.

As a biotech, it competed in a crowded field of novel immuno-oncology platforms. As Saentra Forge, it will compete against private equity and industrial buyers for assets in the defense/aerospace sector, where success depends on financial firepower and integration expertise.